RecruitingPhase 2NCT06551844

Adaptive Dengue Antiviral Platform Trial

Adaptive Dengue Antiviral Platform Trial (ADAPT): a Phase 2 Randomized, Adaptive, Open Label Trial for Antiviral Screening in Patients With Early Symptomatic Dengue

Sponsor

Oxford University Clinical Research Unit, Vietnam

Enrollment

500 participants

Start Date

Apr 20, 2026

Study Type

INTERVENTIONAL

Conditions

Dengue Antiviral Drugs

Summary

This is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection * Primary objectives: * To determine the antiviral effectiveness of the experimental drug(s) in early dengue infection * To assess the safety and tolerability of the experimental drug(s) in dengue patients * Secondary objective: * To assess the effect of the experimental drug(s) in dengue patients on physiological, clinical and virological parameters

Eligibility

Min Age: 10 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Molnupiravir 400 mg, a drug called Remdesivir 100mg, and others for people with antiviral drugs and dengue. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMolnupiravir 400 mg

This is an antiviral drug (an RNA dependent RNA polymerase inhibitor, with broad spectrum antiviral activity) currently approved for use in treatment for COVID-19 patients. In this trial, its antiviral effectiveness on the early phase of dengue virus infection will be assessed.

DRUGVIS513 (a monoclonal antibody)

VIS513 is an engineered humanised monoclonal antibody produced by recombinant DNA technology in a mammalian cell (i.e. Chinese hamster ovary) line. It was discovered in the USA by Visterra Inc and subsequently technology for manufacturing and further development was transferred to Serum Institute of India Pvt. Ltd., Pune, India. It has shown potent, specific neutralization of all four serotypes of DENV.

DRUGRemdesivir 100mg

Remdesivir (GS-443902) is a nucleoside analogue - RNA dependent RNA polymerase inhibitor. In a meta-analysis of 10 RCTs and 32 observational studies reporting on the use of Remdesivir in COVID-19, remdesivir reduced mortality from severe disease and shortened time to clinical improvement. In this trial, its antiviral effectiveness on the early phase of dengue virus infection will be assessed